



Janet T. Mills
Governor

STATE OF MAINE
DEPARTMENT OF PROFESSIONAL & FINANCIAL REGULATION
OFFICE OF PROFESSIONAL AND OCCUPATIONAL REGULATION
BOARD OF PHARMACY



Joan F. Cohen
Commissioner

Penny Vaillancourt
Director

PUBLIC BOARD MEETING
October 2, 2025
AGENDA

Location:

Physical Location: Kennebec Conference Room at the Department of Professional and Financial Regulation, Gardiner Annex, 76 Northern Avenue, Gardiner, ME

Time: 8:30 a.m.

Virtual Zoom Link:

<https://mainestate.zoom.us/j/85419563959?pwd=MWXM4b3RXISoibkQN9H3KanWT63Jtp.1>

The Zoom link for virtual observation is also posted on the board's website

www.maine.gov/pfr/professionallicensing/professions/board-pharmacy/home/board-meeting-information

Board Member Participation:

Board members may participate remotely in Board meetings pursuant to Title 1, Section 403-B and the Board Member Remote Participation Policy adopted by the Board on May 4, 2023.

Public Participation:

Regardless of whether the Board meets in-person or by remote virtual means via Zoom, the public may observe the board meeting in-person at the location described above or may choose to join virtually (see the link above).

Contact: Meagan McLaughlin , Comprehensive Health Planner II
Phone: 207-624-8689
TTY Users Call Maine Relay 711
Email: Meagan.Mclaughlin@maine.gov

I. CALL TO ORDER

II. DRAFT MINUTES REVIEW AND APPROVAL

1. September 4, 2025

III. APPLICATION REVIEW AND BOARD ACTION

Office Location: 76 Northern Avenue, Gardiner, Maine 04345
Mailing Address: 35 State House Station, Augusta, Maine 04333
[Board of Pharmacy | Office of Professional and Occupational Regulation](#)

Phone: (207) 624-8651

TTY: Please Call Maine Relay 711

Fax: (207) 624-8690

Initial Applications

1. Ashley LaRose – PT60019858
2. Matthew Merchant – PT60020173

Renewal Applications

3. Covetrus North America, LLC - MO40003114
4. Covetrus North America, LLC - MO40003121
5. Covetrus North America, LLC - MO40003122
6. Covetrus North America, LLC – PH50001716
7. Covetrus North America, LLC - WH70003254
8. Covetrus North America, LLC - WH70003255
9. Covetrus North America, LLC - WH70003256
10. Covetrus North America, LLC - WH70003257
11. Covetrus North America, LLC - WH70003258
12. Covetrus North America, LLC - WH70003259
13. Covetrus North America, LLC - WH70003260
14. Covetrus North America, LLC - WH70003261
15. Covetrus North America, LLC - WH70003454

IV. COMPLAINT PRESENTATION(S) AND BOARD ACTION

1. 2025-PHA-20815
2. 2025-PHA-20838
3. 2025-PHA-20840
4. 2025-PHA-20841
5. 2025-PHA-20844

V. REQUESTS FOR WAIVER

1. Omni-Care of Maine, CSP50001737, request to amend existing ADM two-way waiver of Board Rule Chapter 20, Subchapter 2, Section 11.

VI. OTHER

1. Maine CDC Standing Orders for COVID-19 Vaccine Issued September 12, 2025
2. FDA Letter Regarding Compounded Drug Products Obtained from Third Parties

VII. DIRECTOR’S REPORT

1. Substance Use Assessments
2. National Association of Boards of Pharmacy Forum – October 27-30, 2025

VIII. 2026 TENTATIVE MEETING SCHEDULE REVIEW

IX. PUBLIC OPPORTUNITY TO COMMENT

(Board President Statement) “Under this item, the Board may offer an opportunity to members of the public listening in to comment on any public matter under the jurisdiction of the Board. While the Board cannot take action on any issues presented, nor can it respond to or debate decisions made today, including matters relating to complaint cases that may be on the agenda. The board will listen to comments and may ask staff to place the issue on a subsequent agenda. At the discretion of the Board President a time limit on comments may be set.”



X. ADJOURNMENT

Pursuant to 1 M.R.S. §406 public notice has been met by publication in an area newspaper where the meeting is held. This is a virtual board meeting and is open to members of the public, but not for public participation. Information to join this meeting is on the Board's website. Please contact Meagan McLaughlin if you wish to confirm this meeting date or check our web site at www.maine.gov/professionallicensing

The Board may address agenda items out of sequence to accommodate persons appearing before the Board or to aid in the efficiency of effectiveness of the meeting. The Board may combine two or more agenda items for consideration. The Board may remove an item from the agenda or delay discussion relating to an item on the

